Display options
Cite
Abo El-Enen M, Tawfik A, El-Abd AS, et al. Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial. Arab J Urol. 2015;14(1):59-65doi: 10.1016/j.aju.2015.09.007.
Abo El-Enen, M., Tawfik, A., El-Abd, A. S., Ragab, M., El-Abd, S., Elrashidy, M., Elmashad, N., Rasheed, M., & El-Abd, S. (2016). Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial. Arab journal of urology, 14(1), 59-65. https://doi.org/10.1016/j.aju.2015.09.007
Abo El-Enen, Mohamed, et al. "Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial." Arab journal of urology vol. 14,1 (2016): 59-65. doi: https://doi.org/10.1016/j.aju.2015.09.007
Abo El-Enen M, Tawfik A, El-Abd AS, Ragab M, El-Abd S, Elrashidy M, Elmashad N, Rasheed M, El-Abd S. Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial. Arab J Urol. 2016 Mar;14(1):59-65. doi: 10.1016/j.aju.2015.09.007. Epub 2015 Nov 21. PMID: 26966595; PMCID: PMC4767797.
Copy Download .nbib Format: NLM
Share it on

Arab J Urol. 2016 Mar;14(1):59-65. doi: 10.1016/j.aju.2015.09.007. Epub 2015 Nov 21.

Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial.

Arab journal of urology

Mohamed Abo El-Enen, Ahmed Tawfik, Ahmed S El-Abd, Maged Ragab, Sherin El-Abd, Mohamed Elrashidy, Nehal Elmashad, Mohamed Rasheed, Shawky El-Abd

Affiliations

  1. Departments of Urology, Faculty of Medicine, Tanta University, Tanta, Egypt.
  2. Departments of Histology, Faculty of Medicine, Tanta University, Tanta, Egypt.
  3. Departments of Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt.
  4. Departments of Medical Oncology, Faculty of Medicine, Tanta University, Tanta, Egypt.

PMID: 26966595 PMCID: PMC4767797 DOI: 10.1016/j.aju.2015.09.007

Abstract

OBJECTIVE: To evaluate the impact of a luteinising hormone-releasing hormone (LHRH) agonist, goserelin acetate (GA), on surgical blood loss during transurethral resection of the prostate (TURP), as well as its histopathological effect on prostatic microvessel density (MVD).

PATIENTS AND METHODS: Patients who underwent TURP due to benign prostatic enlargement (60-100 mL) were randomly subdivided into two equal groups according to whether they received preoperative GA administration (3.6 mg; group A) or not (group B). Evaluation parameters were operative time, weight of resected prostatic tissue, perioperative haematocrit (HCT) changes, estimation of intraoperative blood loss, and suburethral and stromal prostatic MVD. Effects of GA on prostate weight and any possible side-effects were also monitored.

RESULTS: In all, 35 and 33 patients were included in groups A and B, respectively. Operative time and HCT values' changes were significantly less in group A (P < 0.05). Also, operative blood loss (both total and adjusted per weight of resected tissue) was lower in group A, at a mean (SD) of 178.13 (77.71) mL and 3.74 (1.52) mL/g vs 371.75 (91.09) mL and 8.59 (2.42) mL/g (P < 0.001). The median MVD in both suburethral [8 vs 11 vessels/high-power field (HPF)] and stromal tissues (9 vs 17 vessels/HPF) were significantly lower in group A (P < 0.001). Side-effects were minimal.

CONCLUSION: A single dose of GA, a LHRH agonist, before TURP is safe and effective in reducing surgical blood loss. It significantly reduced MVD in both suburethral and stromal nodular prostatic tissues without regional discrepancy.

Keywords: 5ARI, 5α-reductase inhibitor; BPE, benign prostatic enlargement; BPH; Blood loss; CBC, complete blood count; DHT, dihydrotestosterone; GA, goserelin acetate; Goserelin; HCT, haematocrit; HPF, high-power field; LHRH; MVD, microvessel density; MVD-stroma, stromal MVD; MVD-sub, suburethral MVD; TRUS-PV, TRUS prostate volume; TURP; VEGF, vascular endothelial growth factor

References

  1. Scand J Urol Nephrol. 1984;18(2):97-100 - PubMed
  2. J Endourol. 2013 Jan;27(1):68-70 - PubMed
  3. Peptides. 1999;20(10):1247-62 - PubMed
  4. Urology. 1991 Feb;37(2):92-4 - PubMed
  5. J Urol. 2003 Jan;169(1):20-3 - PubMed
  6. BJU Int. 2005 Dec;96(9):1319-22 - PubMed
  7. J Urol. 2000 Dec;164(6):1891-4 - PubMed
  8. J Urol. 2000 Feb;163(2):496-8 - PubMed
  9. Urology. 2009 Jun;73(6):1274-8 - PubMed
  10. Can Urol Assoc J. 2013 Mar-Apr;7(3-4):E226-30 - PubMed
  11. Urology. 2001 Dec;58(6):972-6 - PubMed
  12. Eur Urol. 2006 Nov;50(5):969-79; discussion 980 - PubMed
  13. Asian J Androl. 2011 Nov;13(6):812-8 - PubMed
  14. J Urol. 1993 Jun;149(6):1553-4 - PubMed
  15. Urol Int. 2008;80(2):177-80 - PubMed
  16. Prostate Cancer Prostatic Dis. 2005;8(3):215-8 - PubMed
  17. J Urol. 2002 Apr;167(4):1731-3 - PubMed
  18. Eur Urol. 2000 Apr;37(4):367-80 - PubMed
  19. Urol Int. 2005;74(1):51-3 - PubMed
  20. BJU Int. 2007 Mar;99(3):587-94 - PubMed
  21. Urology. 2000 May;55(5):684-9 - PubMed

Publication Types